CLINICAL AND CARDIOMETABOLIC EFFICACY OF FRUCTOSE-1,6-DIPHOSPHATE (NEOSTIN) THERAPY IN PATIENTS WITH COMORBID CARDIOVASCULAR DISEASES AND TYPE 2 DIABETES MELLITUS

Authors

  • Urinov O.U. Republican Specialized Scientific and Practical Medical Center of Cardiology Tashkent, Uzbekistan
  • Turgunov L.R. Republican Specialized Scientific and Practical Medical Center of Cardiology Tashkent, Uzbekistan
  • Abidova D.E. Republican Specialized Scientific and Practical Medical Center of Cardiology Tashkent, Uzbekistan

Abstract

The article presents the results of a comparative evaluation of the clinical and cardiometabolic efficacy of fructose-1,6-diphosphate (Neostin) in patients with cardiovascular diseases and comorbid type 2 diabetes mellitus. The study included 203 patients who were divided into a main group (n=152), receiving Neostin in addition to standard cardiological and glucose-lowering therapy, and a control group (n=51), receiving conventional therapy. Neostin was administered intravenously at a dose of 5 g once daily for 10 days. The patients were followed for 6 months, with assessment of metabolic, lipid, hematological, coagulation, hemodynamic, functional, echocardiographic, and Holter monitoring parameters. The results demonstrated significant improvements in the main group, including reductions in fasting glucose, HbA1c, total cholesterol, triglycerides, LDL cholesterol, and NT-proBNP levels. Significant improvements were also observed in blood pressure, heart rate, frequency of angina attacks, exercise tolerance, left ventricular ejection fraction, ventricular volumes, left ventricular myocardial mass index, and pulmonary artery systolic pressure. Holter monitoring demonstrated a marked reduction in ventricular and supraventricular extrasystolic activity. Compared with standard therapy, the addition of Neostin was associated with significantly greater positive changes in metabolic control, cardiovascular function, myocardial remodeling, and electrical stability. The findings indicate that fructose-1,6-diphosphate may have a favorable cardiometabolic effect and may be considered as a component of comprehensive therapy in patients with cardiovascular diseases and comorbid type 2 diabetes mellitus.

 

References

1.American Diabetes Association. (2024). 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care, 47(Suppl 1), S179-S218. https://doi.org/10.2337/dc24-S010

2.Lopaschuk, G. D., Karwi, Q. G., Tian, R., et al. (2021). Cardiac Energy Metabolism in Heart Failure and Diabetes. Circulation Research, 128(6), 787-813. https://doi.org/10.1161/CIRCRESAHA.121.318241

3.Jia, G., Hill, M. A., & Sowers, J. R. (2018). Diabetic cardiomyopathy: an update of mechanisms, contributing factors and therapeutic options. Nature Reviews Endocrinology, 14(12), 708-722. https://doi.org/10.1038/s41574-018-0095-1

4.Kenny, H. C., & Abel, E. D. (2019). Heart Failure in Type 2 Diabetes Mellitus: Impact of Glucose-Lowering Therapies, Pathophysiology, and Mechanisms. Circulation Research, 124(1), 121-141. https://doi.org/10.1161/CIRCRESAHA.118.311371

5.Burchfield, J. S., Xie, M., & Hill, J. A. (2013). Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation, 128(4), 388-400. https://doi.org/10.1161/CIRCULATIONAHA.113.001878

6.Tan, Y., Zhang, Z., Yu, C., et al. (2020). Sex-specific differences in diabetic cardiomyopathy: a focus on mitochondrial dysfunction and inflammation. Frontiers in Endocrinology, 11, 571. https://doi.org/10.3389/fendo.2020.00571

7.Bugger, H., & Abel, E. D. (2014). Molecular mechanisms of diabetic cardiomyopathy. Diabetologia, 57(4), 660-671. https://doi.org/10.1007/s00125-014-3171-6

8.Ceriello, A., Prattichizzo, F., & Massi Benedetti, M. (2023). The "metabolic memory" in diabetes: current concepts and future therapeutic perspectives in cardiovascular protection. Lancet Diabetes & Endocrinology, 11(4), 277-289. https://doi.org/10.1016/S2213-8587(23)00021-4

9.Prattichizzo, F., De Nigris, V., Spiga, R., et al. (2021). Inflammation and metabolic memory in diabetes-associated vascular complications: Focus on mitochondrial sub-components. Frontiers in Endocrinology, 12, 652410. https://doi.org/10.3389/fendo.2021.652410

10.Seferovic, P. M., Petrie, M. C., Filippatos, G. S., et al. (2018). Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 20(5), 853-872. https://doi.org/10.1002/ejhf.1170

Published

2026-09-24